United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - olmesartan medoxomil 5 mg - olmesartan medoxomil tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, eva

United States - English - NLM (National Library of Medicine)

jubilant cadista pharmaceuticals inc. - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - olmesartan medoxomil 5 mg - olmesartan medoxomil tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets.  control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detectio

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - hydrochlorothiazide ep; olmesartan medoxomil - film-coated tablet - 20/12.5 - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 20 mg - tablet - excipient ingredients: lactose monohydrate; hyprolose; microcrystalline cellulose; stearic acid; magnesium stearate; titanium dioxide; hypromellose; purified talc - olmesartan medoxomil is indicated for the treatment of hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; stearic acid; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc - olmesartan medoxomil is indicated for the treatment of hypertension.

United States - English - NLM (National Library of Medicine)

apotex corp. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - olmesartan medoxomil ; hydrochlorothiazide ep - film coated tablet - 40/12.5 milligram - olmesartan medoxomil and diuretics

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; stearic acid; hyprolose; purified water; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: magnesium stearate; purified water; stearic acid; hyprolose; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; hyprolose; microcrystalline cellulose; purified water; stearic acid; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.